Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO
TheBody is a service of Remedy Health Media, 461 Fifth Avenue, 14th Floor, New York, NY 10017. TheBody and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBody's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBody is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.